
Chinese biopharmaceutical company founded in December 2004 in Hangzhou, Zhejiang with 40 million yuan of registered capital, designated a national high-tech enterprise and a leading Zhejiang developer and maker of microecological preparations. It joined China Grand Pharmaceutical Group as a wholly owned subsidiary in 2013 and invests heavily each year in microecological and large-molecule drug development, growing revenue at more than thirty percent a year. Its flagship product is a four-strain live Bifidobacterium tablet covered by its own patents, the first Chinese national new drug to combine four bacterial strains from different genera.
Ver perfil de la empresa
Deja tu valoración